BioCentury | Feb 3, 2021
Product Development

Big gain for Cassava on little efficacy data in Alzheimer’s

Cassava more than doubled its share price Tuesday on a small amount of uncontrolled data in Alzheimer’s disease and the disclosure that it will move simufilam to Phase III in the indication. Cassava Sciences Inc....
BioCentury | Jan 20, 2021
Product Development

Alzheimer’s marks fourth late-stage miss for Biohaven’s glutamate modulator

Biohaven’s glutamate modulator troriluzole has missed its primary endpoint in a fourth neurological indication, this time Alzheimer’s disease. That won’t necessarily prevent the company from advancing the therapy. Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) fell...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...
BioCentury | Dec 16, 2020

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

Cancer screening play Singlera raises megaroundSinglera Genomics Inc. raised $150 million in a series B round led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. Fellow new...
BioCentury | Dec 5, 2020
Product Development

Cortexyme’s Alzheimer’s therapy passes futility analysis, but investors aren’t impressed

Cortexyme’s atuzaginstat cleared a major hurdle in its Phase II/III trial for Alzheimer’s disease, passing a planned futility analysis. However, the criteria for passing only required not performing worse than placebo, which apparently didn’t give investors...
BioCentury | Sep 10, 2020

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...Enterprise Associates. Korro Bio develops antisense guide strands that bind target RNA sequences and recruit endogenous adenosine deaminase...
BioCentury | Jun 5, 2020

AstraZeneca adds RNA-modifying targets to oncology pipeline via Accent deal

...with different aspects of RNA biology, including splicing and translational regulation. Targets ADAR (ADAR1) - Adenosine deaminase...
BioCentury | Apr 23, 2020

RNA epigenetic cancer company Accent adds $63M in series B round

...Adenosine deaminase RNA-specific METTL3 - Methyltransferase like 3 Stephen Hansen, Associate Editor Accent Therapeutics Inc. Methyltransferase like 3 (METTL3) Adenosine deaminase...
BioCentury | Apr 20, 2020

French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments

...gained that treatment’s approval in 2016 to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID...
BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

...the chemokine response factor ZC3H12A, the checkpoint regulator VISTA, the transcription factor FLI1 and the adenosine deaminase... characterizes how the ADA2 mutations that cause the rare disease known as deficiency of adenosine deaminase...
...which can be disrupted by blocking iron trafficking ( No. 3059 ). Targets ADA2 - Adenosine deaminase...
Items per page:
1 - 10 of 585